Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sialbio Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 examiner, ZEMAN, ROBERT A, within 1 distinct art unit. This concentration means that the company's current interaction with the patent office is limited to a single point of contact.
The busiest examiner, ZEMAN, ROBERT A, handles the 1 pending office action, representing the entirety of the company's pending workload. With only 1 distinct art unit involved, the prosecution strategy is highly focused on the specific technical requirements of that group within the Biotechnology & Pharmaceuticals field. The 1 to 1 ratio of pending office actions to examiners means that the outcome of this single matter will define the current success of the portfolio.
Practitioners should prioritize understanding the specific preferences of this 1 examiner, as there are no other distinct examiners or art units to provide a broader context for the company's prosecution. This singular focus allows for a very dedicated approach to the 1 pending office action. For a company in the Biotechnology & Pharmaceuticals sector, this single action represents the entirety of their current engagement with the patent office. Success depends on navigating the specific standards of the 1 distinct art unit involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZEMAN, ROBERT A | 1 | 54.2% | +27.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19213610 | Pharmaceutical Composition for Preventing or Treating Sjogren's Syndrome Comprising Anti-SEMA4D Blocking Antibody as Active Ingredient | ZEMAN, ROBERT A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19213610 | Pharmaceutical Composition for Preventing or Treating Sjogren's Syndrome Comprising Anti-SEMA4D Blocking Antibody as Active Ingredient | ZEMAN, ROBERT A | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19213610 | Pharmaceutical Composition for Preventing or Treating Sjogren's Syndrome Comprising Anti-SEMA4D Blocking Antibody as Active Ingredient | ZEMAN, ROBERT A | 1645 | §101§102§103§112 | Non-Final OA | — | Pending | May 20, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSialbio Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert A Zeman has the most, with 1 of Sialbio Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
